Pharmaceutical and medical device organizations very often have government mandated responsibilities to study their products in “Real-World” settings. Such research, generally referred to as Phamacoepidemiology (or Medical Device Epidemiology) includes, post marketing surveillance, risk evaluation and mitigation strategies (REMS), drug utilization reviews (DUR), comparative effectiveness research (CER), and post-authorization safety studies (PASS). RWR is an instrumental component in these government mandated research activities.

Health Technology Assessments (HTAs) are used to evaluate the clinical effectiveness, cost-effectiveness, and broader impact of health technologies, including drugs, medical devices, procedures, and interventions. They are often integral to healthcare decision-making processes, particularly regarding the allocation of resources and reimbursement policies. Government agencies often establish frameworks and guidelines that encourage or require HTAs to inform healthcare policy and decision-making. RWR enhances the robustness, relevance, and applicability of HTAs by providing real-world insights into the effectiveness, safety, and value of health technologies. The integration of RWR into HTAs enables informed decisions about the adoption, reimbursement, and utilization of interventions, ultimately improving patient outcomes and optimizing healthcare delivery.

RWR plays a crucial role in demonstrating the value of pharmaceuticals and medical devices to payers, healthcare providers, and healthcare systems. Well planned and executed RWR helps to quantify the real-world impact of interventions on patient outcomes, healthcare utilization, and cost-effectiveness. From a HEOR perspective, RWR can be leveraged to estimate healthcare costs, quality-adjusted life years (QALYs), and other health outcomes associated with different treatment options. In the current healthcare environment, with an ever increasing emphasis on value-based care, RWR is instrumental in supporting value propositions, pricing strategies, and market positioning, and is used to negotiate favorable reimbursement agreements, formulary placement, and coverage decisions.

In addition to MAR & HEOR applications, pharmaceutical and medical device organizations have a variety of pre- and post- product launch commercialization and marketing needs that can be aided with the appropriate use of RWR. RWR aids with the identification of target patient populations, understanding treatment patterns, and the assessment of market dynamics. By analyzing real-world treatment pathways, patient characteristics, and healthcare utilization patterns, companies can tailor their commercialization strategies, marketing efforts, and market access initiatives to meet the needs of specific patient populations and healthcare providers.

Non-product commercialization, such as public health communications, can also be aided by similar RWR applications.

An increasing use of RWR is in support of clinical trials. A few of the potential applications of RWR in clinical trials are:

1) to inform trial optimization,

2) to identify potential sites and investigators, and

3) to provide external controls.

Pragmatic trials are designed to evaluate the effectiveness of interventions in real-world clinical practice settings, reflecting routine care conditions. This study design incorporates key components of a clinical trial, most notably randomization, but with broader inclusion criteria, more flexible protocols, and minimal interference with routine clinical practice.